Skip to main content
Abbott logo

Abbott

3.8
ABT

A Abbott Company

www.abbott.com
Location
Abbott Park, Illinois
Size
10,001+ employees
Revenue
$10+ billion (USD)
Industry
Hospitals and Health Care
Founded
1888

Global Healthcare Innovation Leader

Abbott stands as a global healthcare powerhouse with over 135 years of innovation, helping people live fuller, healthier lives through life-changing technologies and solutions. Founded in 1888 and headquartered in Abbott Park, Illinois, this Fortune 500 company employs more than 114,000 professionals across 160+ countries, creating breakthrough medical devices, diagnostics, nutrition products, and branded generic medicines that touch millions of lives daily.

Comprehensive Healthcare Solutions

Abbott's portfolio spans the entire healthcare spectrum-from cutting-edge diagnostics that quickly identify medical needs to revolutionary medical devices that treat conditions effectively. The company's commitment to personal healthcare technologies empowers individuals with critical data and knowledge, positioning Abbott at the forefront of healthcare transformation and patient-centered care delivery.

Career Opportunities and Professional Growth

  • Over 2,200 active career opportunities across multiple disciplines and locations
  • Global career development programs within a supportive, collaborative community
  • Meaningful work that directly impacts patient outcomes and healthcare advancement
  • Locally competitive compensation and comprehensive benefits packages
  • Workplace culture emphasizing innovation, scientific rigor, and professional excellence

Diverse Opportunities Across America

With significant operations throughout Illinois, California, Minnesota, Texas, Ohio, Massachusetts, and New Jersey, Abbott offers diverse career paths in research and development, manufacturing, sales, regulatory affairs, and corporate functions. Team members contribute to work that matters, developing solutions that help people get back to doing what they love while shaping the future of medicine.

Making a Global Impact

Abbott's focus on employee development, combined with its commitment to addressing global health challenges through science and compassionate care, creates an environment where healthcare professionals build meaningful careers. Whether advancing diagnostics, developing medical devices, or supporting operations, Abbott team members are revolutionizing healthcare and improving lives worldwide.

Mission

Abbott helps people live more fully at all stages of life through life-changing healthcare technologies, diagnostics, nutrition products, and medicines that serve people in more than 160 countries.

Frequently Asked Questions

Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation

Positive 12-month results from the VOLT-AF IDE Study presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforce the Volt(TM) Pulsed Field Ablation (PFA) System's industry-leading success rate for treating AFib1 New data from the FOCALFLEX CE Mark trial demonstrate the safety and efficacy of the TactiFlex(TM) Duo Ablation Catheter, Sensor Enabled(TM), to significantly reduce AFib episodes for complex cases2 ABBOTT PARK, Ill., Feb. 6, 2026...

Read Full Article

Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook

Fourth-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.50 reflects growth of 12 percent Full-year 2025 GAAP diluted EPS of $3.72; adjusted diluted EPS of $5.15 reflects growth of 10 percent Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5% Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects 10 percent growth at the midpoint ABBOTT PARK, Ill., Jan. 22, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced...

Read Full Article

Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms

Abbott's TactiFlex(TM) Duo Ablation Catheter, Sensor Enabled(TM), is designed with dual-energy to treat atrial fibrillation patients with the most challenging cases It can deliver both radiofrequency energy and pulsed field ablation (PFA) energy during procedures to target and treat an irregular heart rhythm The availability of TactiFlex Duo in Europe adds a dual-energy, focal ablation catheter to Abbott's growing PFA portfolio, following the company's Volt PFA System approvals in the U.S....

Read Full Article

Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions

Traditional food logging apps offer feedback after the fact-Libre Assist1 offers help in-the-moment to inform mealtime decisions before every bite Libre Assist1 leverages AI to predict how food choices affect glucose levels,2 provides personalized meal guidance,3 and confirms glucose impact using data from Abbott's world-leading FreeStyle Libre continuous glucose monitoring (CGM) technology4 Abbott is launching Libre Assist, available at no additional cost within the Libre app,5 during CES(R)...

Read Full Article

Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation

Abbott's Volt(TM) PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib) Pulsed field ablation - or PFA - is a minimally invasive procedure that uses high-energy electrical pulses in targeted areas of the heart to treat irregular heart rhythms Abbott's Volt PFA System is an all-in-one product that is clinically proven to simplify the treatment of AFib that is gentler on the heart, has shorter...

Read Full Article